Sazzad Faizus, Kuzemczak Michał, Loh Engracia, Wu Wellington, Kofidis Theo
Myocardial Experimental Laboratory, Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, 02-507 Warsaw, Poland.
Biomedicines. 2021 May 24;9(6):595. doi: 10.3390/biomedicines9060595.
A 3-dimensional, robust, and sustained myocardial restoration by means of tissue engineering remains an experimental approach. Prolific protocols have been developed and tested in small and large animals, but, as clinical cardiac surgeons, we have not arrived at the privilege of utilizing any of them in our clinical practice. The question arises as to why this is. The heart is a unique organ, anatomically and functionally. It is not an easy target to replicate with current techniques, or even to support in its viability and function. Currently, available therapies fail to reverse the loss of functional cardiac tissue, the fundamental pathology remains unaddressed, and heart transplantation is an ultima ratio treatment option. Owing to the equivocal results of cell-based therapies, several strategies have been pursued to overcome the limitations of the current treatment options. Preclinical data, as well as first-in-human studies, conducted to-date have provided important insights into the understanding of injection-based approaches for myocardial restoration. In light of the available data, injectable biomaterials suitable for transcatheter delivery appear to have the highest translational potential. This article presents a current state-of-the-literature review in the field of hydrogel-based myocardial restoration therapy.
通过组织工程实现三维、强健且持久的心肌修复仍是一种实验性方法。已经开发并在大小动物身上测试了多种方案,但作为临床心脏外科医生,我们尚未有幸在临床实践中使用其中任何一种。问题在于为何会如此。心脏在解剖学和功能上都是一个独特的器官。用当前技术复制它并非易事,甚至维持其生存能力和功能也不容易。目前,现有的治疗方法无法逆转功能性心脏组织的损失,基本病理问题仍未得到解决,心脏移植是最后的治疗选择。由于基于细胞的疗法结果不明确,人们采取了多种策略来克服当前治疗方案的局限性。迄今为止进行的临床前数据以及首次人体研究为理解基于注射的心肌修复方法提供了重要见解。根据现有数据,适用于经导管递送的可注射生物材料似乎具有最高的转化潜力。本文对基于水凝胶的心肌修复治疗领域的当前文献进行综述。